- HPLC-assayed purity of ≥99%
- Certificate of analysis tied to your lot number
- Tracked EU delivery, dispatched the next working day
Tesamorelin (Egrifta-type) — Prescription Reference
Pharmaceutical-grade GHRH(1–44) analogue — reference entry, prescription only
In stock1 format availableCAS 218949-48-5
€382
This listing is currently unavailable. Contact us and we will tell you when it is back or suggest an equivalent.
Ask about this listing or request its COA- Mol. weight5,135.86 g/mol
For laboratory research use only. Sold exclusively for in-vitro laboratory research by qualified professionals. Not for human or veterinary use, and not a medicine, food, cosmetic or dietary supplement. Terms and Conditions
Overview
Key facts
Reference entry for a prescription-only medicine.
- CAS number
- 218949-48-5
- Molecular formula
- C221H366N72O67S
- Molecular weight
- 5,135.86 g/mol
- Storage
- Per the approved labelling for the specific formulation — some presentations require 2–8 °C refrigeration, later reformulations are stable at controlled room…
- Available size
- 2 mg vial · 30-pack
For research use only. Not for human consumption.
Reference entry for a prescription-only medicine. What is described here is the authorised, pharmaceutical-grade tesamorelin sold as the Egrifta range — not research-grade material. We include it in our institutional catalogue so that clinics and pharmacies can look up the molecule, its single authorised use, how it is presented and how to store it. It is released only on a valid prescription or with an institution's documented authorisation, and you will find no guidance here on dosing, administration or where to source it.
Chemically, tesamorelin is a man-made form of growth hormone-releasing hormone (GHRH): all 44 amino acids of the human sequence plus a trans-3-hexenoyl group on the first tyrosine. This acyl cap covers the exact site at which DPP-4 splits natural GHRH, which is why the molecule holds up better. In its acetate-salt form the peptide weighs 5,135.86 g/mol and has the formula C221H366N72O67S.
What sets this listing apart
Tesamorelin (Egrifta-type) – vial, 2 mg. Other Tesamorelin listings differ in format, fill or combination partners; the specification and COA always refer to the listing you order.
Same compound, other listings
Specifications
Identity
- CAS number
- 218949-48-5
- Molecular formula
- C221H366N72O67S
- Molecular weight
- 5,135.86 g/mol
- Peptide class
- Growth hormone-releasing hormone (GHRH) analogue; growth hormone secretagogue
Additional detail
- Regulatory status
- Prescription-only medicine (Rx); supplied solely against valid prescription or institutional authorisation
- Generic name
- Tesamorelin acetate
- Approved brand family
- Egrifta, Egrifta SV and Egrifta WR formulations
- Structure
- Full 44-residue human GHRH sequence with a trans-3-hexenoyl group on the N-terminal tyrosine
- Molecular target
- GHRH receptor on anterior pituitary somatotrophs
- Downstream marker
- Endogenous pulsatile growth hormone release, with a consequent rise in IGF-1
- Approved indication
- Reduction of excess abdominal fat in adults with HIV infection and lipodystrophy
- Reference size listed
- 2 mg vial × 30
- Storage
- Per the approved labelling for the specific formulation — some presentations require 2–8 °C refrigeration, later reformulations are stable at controlled room temperature; reconstituted solution used per labelling
Questions about Tesamorelin (Egrifta-type) — Prescription Reference
Can tesamorelin be obtained without a prescription?
No. The pharmaceutical product on this page requires a prescription. The entry covers identity, pharmacology, the authorised indication and storage for institutional reference only; supply happens solely against a valid prescription or an institution's documented approval, and we offer no other way to obtain it.
How is it different from growth hormone itself?
It acts one step earlier. As a GHRH receptor agonist on pituitary somatotrophs, it makes the patient's own pituitary release growth hormone in pulses that stay under IGF-1 and somatostatin feedback. Somatropin, by contrast, is growth hormone given directly, bypassing that control loop.
What is the role of the trans-3-hexenoyl group?
It caps the N-terminal tyrosine of the 44-residue GHRH sequence exactly where dipeptidyl peptidase-4 would cut and inactivate native GHRH. The bulky hydrophobic group blocks that cleavage without touching the receptor-binding part of the peptide — the basis of its greater stability.
Why don't all presentations have the same storage instructions?
The product has been reformulated over time. Older vial versions needed to be kept refrigerated (2–8 °C); newer ones were engineered to stay stable at controlled room temperature and use other reconstitution volumes and vial strengths. The authorised product information for the specific pack you hold always takes precedence.
Related
